Summary: GHK-Cu (copper peptide) has shown promise for hair loss in preclinical studies, but no robust human clinical trials have confirmed its efficacy, and it is not recommended by NICE or NHS as an evidence-based treatment
Thats why we will always carry out our own assessment before we begin the treatment
Optimized volume/price ratio, extended autonomy (several weeks at typical 250-500 mcg dose), final concentration adjustable to protocol (5 mg/ml with 2 ml bacteriostatic, or 2.5 mg/ml with 4 ml for finer dosing)
Hybrid models handle final QC and lyophilization domestically while sourcing raw synthesized sequences from contract facilities, often in the US or Europe
Although NRPS product assembly frequently seems to display a strict correlation between the enzymatic domain sequence of the megasynthase and the position of the amino acid building blocks in the peptide product, this colinearity rule is not strictly reinforced in nature 36,37